Management of Nonmotor Symptoms of Parkinson's Disease

doi:10.1017/CBO9781107284210.010

Section II - Management of Nonmotor Symptoms of Parkinson's Disease

Published online by Cambridge University Press: 05 March 2016

Edited by

Néstor Gálvez-Jiménez ,

Hubert H. Fernandez ,

Alberto J. Espay and

Susan H. Fox

Show author details

Néstor Gálvez-Jiménez: Affiliation:
Cleveland Clinic, Florida
Hubert H. Fernandez: Affiliation:
Cleveland Clinic, Ohio
Alberto J. Espay: Affiliation:
University of Cincinnati
Susan H. Fox: Affiliation:
Toronto Western Hospital

Book contents

Get access

Type: Chapter
Information: Parkinson's Disease
Current and Future Therapeutics and Clinical Trials
, pp. 93 - 174

DOI: https://doi.org/10.1017/CBO9781107284210.010 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Postuma, RB, Gagnon, JF, Pelletier, A, Montplaisir, J. Prodromal autonomic symptoms and signs in Parkinson's disease and dementia with Lewy bodies. Mov Disord 2013; 28: 597–604.CrossRef Google Scholar PubMed

Muller, B, Larsen, JP, Wentzel-Larsen, T, Skeie, GO, Tysnes, OB, Parkwest Study Group. Autonomic and sensory symptoms and signs in incident, untreated Parkinson's disease: frequent but mild. Mov Disord 2011; 26: 65–72.CrossRef Google Scholar PubMed

Gallagher, DA, Lees, AJ, Schrag, A. What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them? Mov Disord 2010; 25: 2493–500.CrossRef Google Scholar

Stubendorff, K, Aarsland, D, Minthon, L, Londos, E. The impact of autonomic dysfunction on survival in patients with dementia with Lewy bodies and Parkinson's disease with dementia. PLoS One 2012; 7: e45451.Google Scholar

Perez-Lloret, S, Rey, MV, Pavy-Le Traon, A, Rascol, O. Emerging drugs for autonomic dysfunction in Parkinson's disease. Expert Opin Emerging Drugs 2013; 18: 39–53.Google Scholar

Pfeiffer, RF. Autonomic dysfunction in Parkinson's disease. Expert Rev Neurother 2012; 12: 697–706.CrossRef Google Scholar PubMed

Ziemssen, T, Reichmann, H. Cardiovascular autonomic dysfunction in Parkinson's disease. J Neurol Sci 2010; 289: 74–80.Google Scholar

Asahina, M, Vichayanrat, E, Low, DA, Iodice, V, Mathias, CJ. Autonomic dysfunction in parkinsonian disorders: Assessment and pathophysiology. J Neurol Neurosurg Psychiatry 2013; 84: 674–80.CrossRef Google Scholar PubMed

Lim, SY, Moro, E, Tan, AH, Lang, AE. Non-motor symptoms of Parkinson's disease and the effects of deep brain stimulation. In: Chaudhuri, , KR, Tolosa, , E, Schapira, , A, Poewe, , W, eds. Non-Motor Symptoms of Parkinson’s Disease, 2nd edn. Oxford:Oxford University Press, 2014; 394–419.Google Scholar

Seppi, K, Weintraub, D, Coelho, M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011; 26 (Suppl. 3): S42–80.CrossRef Google Scholar PubMed

Jamnadas-Khoda, J, Koshy, S, Mathias, CJ, et al. Are current recommendations to diagnose orthostatic hypotension in Parkinson's disease satisfactory? Mov Disord 2009; 24: 1747–51.CrossRef Google Scholar PubMed

Low, PA, Gilden, JL, Freeman, R, Sheng, KN, McElligott, MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: a randomized, double-blind multicenter study. JAMA 1997; 277: 1046–51.Google Scholar

Freeman, R. Neurogenic orthostatic hypotension. N Engl J Med 2008; 358: 615–24.CrossRef Google Scholar PubMed

Low, PA, Singer, W. Management of neurogenic orthostatic hypotension: an update. Lancet Neurol 2008; 7: 451–58.Google Scholar

Metzler, M, Duerr, S, Granata, R, et al. Neurogenic orthostatic hypotension: Pathophysiology, evaluation, and management. J Neurol 2013; 260: 2212–9.CrossRef Google Scholar PubMed

Senard, JM, Chamontin, B, Rascol, A, Montastruc, JL. Ambulatory blood pressure in patients with Parkinson's disease without and with orthostatic hypotension. Clin Auton Res 1992; 2: 99–104.Google Scholar

Maule, S, Papotti, G, Naso, D, et al. Orthostatic hypotension: Evaluation and treatment. Cardiovasc Haematol Disord Drug Targets 2007; 7: 63–70.Google Scholar

Perez-Lloret, S, Rey, MV, Fabre, N, et al. Factors related to orthostatic hypotension in Parkinson's disease. Parkinsonism Rel Disord 2012; 18: 501–5.CrossRef Google Scholar PubMed

Mostile, G, Jankovic, J. Treatment of dysautonomia associated with Parkinson's disease. Parkinsonism Related Disord 2009; 15 (Suppl. 3): S224–32.CrossRef Google Scholar PubMed

Schoffer, KL, Henderson, RD, O'Maley, K, O'sullivan, JD. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord 2007; 22: 1543–9.CrossRef Google Scholar PubMed

Kaufmann, H, Freeman, R, Biaggioni, I, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology 2014; 83: 328–335Google Scholar

Hoehn, MM. Levodopa-induced postural hypotension treatment with fludrocortisone. Arch Neurol 1975; 32: 50–1.CrossRef Google Scholar PubMed

Jankovic, J, Gilden, JL, Hiner, BC, et al. Neurogenic orthostatic hypotension: A double-blind, placebo-controlled study with midodrine. Am J Med 1993; 95: 38–48.Google Scholar

Corsini, GU, Del Zompo, M, Gessa, GL, Mangoni, A. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease. Lancet 1979; 313: 954–6.CrossRef Google Scholar

Lang, AE. Acute orthostatic hypotension when starting dopamine agonist therapy in Parkinson disease: the role of domperidone therapy. Arch Neurol 2001; 58: 835.Google Scholar

Hauser, RA, Hewitt, LA, Isaacson, S. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A). J Parkinsons Dis 2013; 4: 57–65.Google Scholar

Sandroni, P, Opfer-Gehrking, TL, Singer, W, Low, PA. Pyridostigmine for treatment of neurogenic orthostatic hypertension: a follow-up survey study. Clin Auton Res 2005; 15: 51–3.CrossRef Google Scholar PubMed

Singer, W, Sandroni, P, Opfer-Gehrking, TL, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol 2006; 63: 513–18.Google Scholar

Shibao, C, Okamoto, LE, Gamboa, A, et al. Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. Hypertension 2010; 56: 847–51.Google Scholar

Suchowersky, O, Furtado, S, Rohs, G. Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson's disease. Mov Disord 1995; 10: 337–40.Google Scholar

Lahrmann, H, Cortelli, P, Hilz, M, et al. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol 2006; 13: 930–6.Google Scholar

Ziemssen, T, Reichmann, H. Treatment of dysautonomia in extrapyramidal disorders. Ther Adv Neurol Disord 2010; 3: 53–67.Google Scholar

Sahul, ZH, Trusty, JM, Erickson, M, Low, PA, Shen, WK. Pacing does not improve hypotension in patients with severe orthostatic hypotension – a prospective randomized cross-over pilot study. Clin Auton Res 2004; 14: 255–8.Google Scholar

Salat-Foix, D, Suchowersky, O. The management of gastrointestinal symptoms in Parkinson's disease. Expert Rev Neurother 2012; 12: 239–48.Google Scholar

Stevens, JE, Jones, KL, Rayner, CK, Horowitz, M. Pathophysiology and pharmacotherapy of gastroparesis: Current and future perspectives. Expert Opin Pharmacother 2013; 14: 1171–86.CrossRef Google Scholar PubMed

Parkes, JD. Domperidone and Parkinson's disease. Clin Neuropharmacol 1986; 9: 517–32.Google Scholar

Soykan, I, Sarosiek, I, Shifflett, J, Wooten, GF, McCallum, RW. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease. Mov Disord 1997; 12: 952–7.Google Scholar

Sakakibara, R, Kishi, M, Ogawa, E, et al. Bladder, bowel, and sexual dysfunction in Parkinson's disease. Parkinson’s Disease 2011; 924605.Google Scholar PubMed

Critchley, P, Langdon, N, Parkes, JD, et al. Domperidone. Br Med J 1985; 290: 788.Google Scholar

Malek, NM, Grosset, KA, Stewart, D, Macphee, GJA, Grosset, DG. Prescription of drugs with potential adverse effects on cardiac conduction in Parkinson's disease. Parkinsonism Rel Disord 2013; 19: 586–9.Google Scholar

Tack, J, Camilleri, M, Chang, L, et al. Systematic review: Cardiovascular safety profile of 5-HT4 agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 2012; 35: 745–67.CrossRef Google Scholar PubMed

Asai, H, Udaka, F, Hirano, M, et al. Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson's disease. Parkinsonism Relat Disord 2005; 11: 499–502.CrossRef Google Scholar PubMed

Pfeiffer, RF. Gastrointestinal dysfunction in Parkinson's disease. Parkinsonism Rel Disord 2011; 17: 10–15.Google Scholar

Jost, WH. Gastrointestinal dysfunction in Parkinson's disease. J Neurol Sci 2010; 289: 69–73.Google Scholar

Bosshard, W, Dreher, R, Schnegg, JF, Bula, CJ. The treatment of chronic constipation in elderly people: An update. Drugs Aging 2004; 21: 911–30.Google Scholar

Astarloa, R, Mena, MA, Sánchez, V, de la Vega, L, de Yébenes, JG. Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease. Clin Neuropharmacol. 1992; 15: 375–80.CrossRef Google Scholar

Ashraf, W, Pfeiffer, RF, Park, F, Lof, J, Quigley, EM. Constipation in Parkinson's disease: objective assessment and response to psyllium. Mov Disord 1997; 12: 946–51.Google Scholar

Ramkumar, D, Rao, SS. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol 2005; 100: 936–71.Google Scholar

Sturtzel, B, Mikulits, C, Gisinger, C, Elmadfa, I. Use of fiber instead of laxative treatment in a geriatric hospital to improve the wellbeing of seniors. J Nutr Health Aging 2009;13: 136–9.CrossRef Google Scholar

Muller, B, Assmus, J, Larsen, JP, et al. Autonomic symptoms and dopaminergic treatment in de novo Parkinson's disease. Acta Neurol Scand 2013; 127: 290–4.Google Scholar

Eichhorn, TE, Oertel, WH. Macrogol 3350/electrolyte improves constipation in Parkinson's disease and multiple system atrophy. Mov Disord 2001; 16: 1176–7.Google Scholar

Zangaglia, R, Martignoni, E, Glorioso, M, et al. Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study. Mov Disord 2007; 22: 1239–44.Google Scholar

Kirkman, MS, Zimmerman, DR, Filippini, SA. Marked deterioration in glycemic control with change in brand of lactulose syrup. South Med J 1995; 88: 492–3.CrossRef Google Scholar PubMed

Muller-Lissner, SA1, Kamm, MA, Scarpignato, C, Wald, A. Myths and misconceptions about chronic constipation. Am J Gastroenterol 2005; 100: 232–42.CrossRef Google Scholar PubMed

Liu, Z, Sakakibara, R, Odaka, T, et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord 2005; 20: 680–6.Google Scholar

Camilleri, M, Kerstens, R, Rykx, A, Vandeplassche, L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008; 358: 2344–54.Google Scholar

Cassani, E, Privitera, G, Pezzoli, G, et al. Use of probiotics for the treatment of constipation in Parkinson's disease patients. Minerva Gastroenterol Dietol 2011; 57: 117–21.Google Scholar PubMed

Ondo, WG, Kenney, C, Sullivan, K, et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology 2012; 78: 1650–4.Google Scholar

Sandyk, R, Gillman, MA. Colchicine ameliorates constipation in Parkinson's disease. J R Soc Med 1984; 77: 1066.Google Scholar

Sakakibara, R, Odaka, T, Lui, Z, et al. Dietary herb extract dai-kenchu-to ameliorates constipation in parkinsonian patients (Parkinson's disease and multiple system atrophy). Mov Disord 2005; 20: 261–2.CrossRef Google Scholar PubMed

Pfeiffer, RF, Markopoulou, K, Quigley, EM, Stambler, N, Cedarbaum, IM. Effect of NT-3 on bowel function in Parkinson's disease. Mov Disord 2002; 17: 223–4.Google Scholar

Chiu, CM, Wang, CP, Sung, WH, et al. Functional magnetic stimulation in constipation associated with Parkinson's disease. J Rehabil Med 2009; 41: 1085–9.Google Scholar

Albanese, A, Brisinda, G, Bentivoglio, AR, Maria, G. Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A. Am J Gastroenterol 2003; 98: 1439–40.Google Scholar

Cadeddu, F, Bentivoglio, AR, Brandara, F, et al. Outlet type constipation in Parkinson's disease: Results of botulinum toxin treatment. Aliment Pharmacol Ther 2005; 22: 997–1003.Google Scholar

Mathers, SE, Kempster, PA, Law, PJ, et al. Anal sphincter dysfunction in Parkinson's disease. Arch Neurol 1989; 46: 1061–4.Google Scholar

Edwards, LL, Quigley, EM, Harned, RK, Hofman, R, Pfeiffer, RF. Defecatory function in Parkinson's disease: Response to apomorphine. Ann Neurol 1993; 33: 490–3.CrossRef Google Scholar PubMed

South, AR, Somers, SM, Jog, MS. Gum chewing improves swallow frequency and latency in Parkinson patients: a preliminary study. Neurology 2010; 74: 1198–202.CrossRef Google Scholar PubMed

Merello, M. Sialorrhoea and drooling in patients with Parkinson's disease: epidemiology and management. Drugs Aging 2008; 25: 1007–19.Google Scholar

Arbouw, MEL, Movig, KLL, Koopmann, M, et al. Glycopyrrolate for sialorrhea in Parkinson disease: A randomized, double-blind, crossover trial. Neurology 2010; 74: 1203–7.Google Scholar

Hyson, HC, Johnson, AM, Jog, MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord 2002; 17: 1318–20.Google Scholar

Pfeiffer, RF. Gastrointestinal, urological, and sexual dysfunction in Parkinson's disease. Mov Disord 2010; 25 (Suppl. 1): S94–7.Google Scholar

Thomsen, TR, Galpern, WR, Asante, A, Arenovich, T, Fox, SH. Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease. Mov Disord 2007; 22: 2268–73.CrossRef Google Scholar PubMed

Ondo, WG, Hunter, C, Moore, W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 2004; 62: 37–40.Google Scholar

Guidubaldi, A, Fasano, A, Ialongo, T, et al. Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease. Mov Disord 2011; 26: 313–19.Google Scholar

Postma, A-G, Heesters, MAAM, van Laar, T. Radiotherapy to the salivary glands as treatment of sialorrhea in patients with parkinsonism. Mov Disord 2007; 22: 2430–5.Google Scholar

Winge, K, Fowler, CJ. Bladder dysfunction in parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord 2006; 21: 737–45.Google Scholar

Blackett, H, Walker, R, Wood, B. Urinary dysfunction in Parkinson's disease: a review. Parkinsonism Related Disord 2009; 15: 81–7.Google Scholar

Nitti, V. Clinical testing for overactive bladder. Can Urol Assoc J 2011; 5 (Suppl.2): S137–8.Google Scholar

Ouslander, JG. Geriatric considerations in the diagnosis and management of overactive bladder. Urology 2002; 60 (Suppl. 1): 50–5.Google Scholar

Cameron, AP, Jimbo, M, Heidelbaugh, JJ. Diagnosis and office-based treatment of urinary incontinence in adults. Part two: treatment. Ther Adv Urol 2013; 5: 189–200.Google Scholar

Burgio, KL. Influence of behavior modification on overactive bladder. Urology 2002; 60 (Suppl. 1): 72–6.Google Scholar

Vaughan, CP, Juncos, JL, Burgio, KL, et al. Behavioral therapy to treat urinary incontinence in Parkinson disease. Neurology 2011; 76: 1631–4.Google Scholar

Appell, RA. Pharmacotherapy for overactive bladder: an evidence-based approach to selecting an antimuscarinic agent. Drugs 2006; 66: 1361–70.Google Scholar

Roth, B, Studer, UE, Fowler, CJ, Kessler, TM. Benign prostatic obstruction and Parkinson's disease: Should transurethral resection of the prostate be avoided? J Urol 2009; 181: 2209–13.Google Scholar

Chandiramani, VA, Palace, J, Fowler, CJ. How to recognize patients with parkinsonism who should not have urological surgery. Br J Urol 1997; 80: 100–4.Google Scholar

Giannantoni, A, Conte, A, Proietti, S, et al. Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder. J Urol 2011; 186: 960–4.Google Scholar

Kulaksizoglu, H, Parman, Y. Use of botulinum toxin-A for the treatment of overactive bladder symptoms in patients with Parkinson's disease. Parkinsonism Rel Disord 2010; 16: 531–4.Google Scholar

Brown, RG, Jahanshahi, M, Quinn, N, Marsden, CD. Sexual function in patients with Parkinson's disease and their partners. J Neurol Neurosurg Psychiatry 1990; 53: 480–86.Google Scholar

Bronner, G. Sexual problems in Parkinson's disease: the multidimensional nature of the problem and of the intervention. J Neurol Sci 2011; 310: 139–43.CrossRef Google Scholar PubMed

Bronner, G, Royter, V, Korczyn, AD, Giladi, N. Sexual dysfunction in Parkinson's disease. J Sex Marit Therapy 2004; 30: 95–105.Google Scholar

Basson, R. Sexuality and Parkinson's disease. Parkinsonism Rel Disord 1996; 2: 177–85.Google Scholar

Papatsoris, AG, Deliveliotis, C, Singer, C, Papapetropoulos, S. Erectile dysfunction in Parkinson's disease. Urology 2006; 67: 447–51.Google Scholar

Cleeves, L, Findley, LJ. Bromocriptine induced impotence in Parkinson's disease. Br Med J 1987; 295: 367–8.Google Scholar

Francis, ME, Kusek, JW, Nyberg, LM, Eggers, PW. The contribution of common medical conditions and drug exposures to erectile dysfunction in adult males. J Urol 2007; 178: 591–6.Google Scholar

Bronner, G. Practical strategies for the management of sexual problems in Parkinson's disease. Parkinsonism Rel Disord 2009; 15 (Suppl. 3): S96–100.CrossRef Google Scholar PubMed

Lim, SY, Evans, AH, Miyasaki, JM. Impulse control and related disorders in Parkinson's disease: review. Ann N Y Acad Sci 2008; 1142: 85–107.Google Scholar

Bronner, G, Vodusek, DB. Management of sexual dysfunction in Parkinson's disease. Ther Adv Neurol Disord 2011; 4: 375–83.Google Scholar

Fine, J, Lang, AE. Dose-induced penile erections in response to ropinirole therapy for Parkinson's disease. Mov Disord 1999; 14: 701–3.Google Scholar

O'sullivan, JD, Hughes, AJ. Apomorphine-induced penile erections in Parkinson's disease. Mov Disord 1998; 13: 536–9.Google Scholar

Briganti, A, Salonia, A, Gallina, A. Drug insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction. Nat Clin Pract Urol 2005; 2: 239–47.Google Scholar

Hussain, IF, Brady, CM, Swinn, MJ, Mathias, CJ, Fowler, CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001; 71: 371–4.Google Scholar

Zesiewicz, TA, Helal, M, Hauser, RA. Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease. Mov Disord 2000; 15: 305–8.Google Scholar

Chrysant, SG. Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension. Curr Hypertens Rep 2013; 15: 475–83.Google Scholar

Giammusso, B, Raffaele, R, Vecchio, I, et al. Sildenafil in the treatment of erectile dysfunction in elderly depressed patients with idiopathic Parkinson's disease. Arch Gerontol Geriatr Suppl 2002; 8: 157–63.Google Scholar

Raffaele, R, Vecchio, I, Giammusso, B, et al. Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease. Eur Urol 2002; 41: 382–6.Google Scholar

Okun, MS, McDonald, WM, , R. DeLong, M. Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency: a common unrecognized comorbidity. Arch Neurol 2002; 59: 807–11.CrossRef Google Scholar PubMed

Okun, MS, Walter, BL, McDonald, WM, et al. Beneficial effects of testosterone replacement for the nonmotor symptoms of Parkinson disease. Arch Neurol 2002; 59: 1750–3.Google Scholar

Okun, MS, Fernandez, HH, Rodriguez, RL, et al. Testosterone therapy in men with Parkinson disease: results of the TEST-PD study. Arch Neurol 2006; 63: 729–35.Google Scholar

Ready, RE, Friedman, J, Grace, J, Fernandez, H. Testosterone deficiency and apathy in Parkinson's disease: a pilot study. J Neurol Neurosurg Psychiatry 2004; 75: 1323–6.Google Scholar

Witjas, T, Kaphan, E, Azulay, JP, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002; 59: 408–13.Google Scholar

Swinn, L, Schrag, A, Viswanathan, R, et al. Sweating dysfunction in Parkinson's disease. Mov Disord 2003; 18: 1459–63.Google Scholar

References

Aarsland, D, Zaccai, J, Brayne, C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005; 20: 1255–63.Google Scholar

Aarsland, D, Andersen, K, Larsen, JP, Lolk, A, Kragh-Sorensen, P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60: 387–92.Google Scholar

Aarsland, , , D, Karlsen, K. Neuropsychiatric aspects of Parkinson's disease. Curr Psychiatry Rep 1999; 1: 61–8.Google Scholar

Hughes, TA, Ross, HF, Mindham, RH, Spokes, EG. Mortality in Parkinson's disease and its association with dementia and depression. Acta Neurol Scand 2004; 110: 118–23.Google Scholar

Muslimovic, D, Post, B, Speelman, JD, De Haan, RJ, Schmand, B. Cognitive decline in Parkinson's disease: a prospective longitudinal study. J Int Neuropsychol Soc 2009; 15: 426–37.Google Scholar

Goldman, JG, Litvan, I. Mild cognitive impairment in Parkinson's disease. Minerva Med 2011; 102: 441–59.Google Scholar

Litvan, I, Aarsland, D, Adler, CH, et al. MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord 2011; 26: 1814–24.Google Scholar

Aarsland, D, Bronnick, K, Williams-Gray, C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010; 75: 1062–9.Google Scholar

Janvin, CC, Larsen, JP, Aarsland, D, Hugdahl, K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006; 21: 1343–9.Google Scholar

Mamikonyan, E, Moberg, PJ, Siderowf, A, et al. Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores. Parkinsonism Relat Disord 2009; 15: 226–31.CrossRef Google Scholar PubMed

Woods, SP, Tröster, AI. Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson's disease. Journal of the International Neuropsychological Society 2003; 9: 17–24.Google Scholar

Owen, AM. Cognitive dysfunction in Parkinson's disease: the role of frontostriatal circuitry. Neuroscientist 2004; 10: 525–37.Google Scholar

Zgaljardic, DJ, Borod, JC, Foldi, NS, Mattis, P. A review of the cognitive and behavioral sequelae of Parkinson's disease: relationship to frontostriatal circuitry. Cogn Behav Neurol 2003; 16: 193–210.Google Scholar

Zgaljardic, DJ, Borod, JC, Foldi, NS, et al. An examination of executive dysfunction associated with frontostriatal circuitry in Parkinson's disease. J Clin Exp Neuropsychol 2006; 28: 1127–44.Google Scholar

Filoteo, JV, Maddox, WT. Quantitative modeling of visual attention processes in patients with Parkinson's disease: effects of stimulus integrality on selective attention and dimensional integration. Neuropsychology 1999; 13: 206–22.CrossRef Google Scholar PubMed

Gabrieli, JD, Singh, J, Stebbins, GT, Goetz, CG. Reduced working memory span in Parkinson’ disease: evidence for the role of a frontostriatal system in working and strategic memory. Neuropsychology 1996 10: 322–32.Google Scholar

Owen, AM, Sahakian, BJ, Hodges, JR, Summers, BA. Dopamine-dependent frontostriatal planning deficits in early Parkinson's disease. Neuropsychology 1995; 9: 126–40.Google Scholar

Richards, M, Cote, LJ, Stern, Y. Executive function in Parkinson's disease: set-shifting or set-maintenance? J Clin Exp Neuropsychol 1993; 15: 266–79.Google Scholar

Filoteo, JV, Rilling, LM, Cole, B, et al. Variable memory profiles in Parkinson's disease. J Clin Exp Neuropsychol 1997; 19: 878–88.Google Scholar

Weintraub, D, Moberg, PJ, Culbertson, WC, et al. Dimensions of executive function in Parkinson's disease. Dement Geriatr Cogn Disord 2005; 20: 140–4.Google Scholar

Higginson, CI, King, DS, Levine, D, et al. The relationship between executive function and verbal memory in Parkinson's disease. Brain Cogn 2003; 52: 343–52.Google Scholar

Taylor, AE, Saint-Cyr, JA, Lang, AE. Memory and learning in early Parkinson's disease: evidence for a “frontal lobe syndrome”. Brain Cogn 1990; 13: 211–32.Google Scholar

Levin, BE, Llabre, MM, Reisman, S, et al. Visuospatial impairment in Parkinson's disease. Neurology 1991; 41: 365–9.Google Scholar

Montse, A, Pere, V, Carme, , J, Francesc, , V, Eduardo, T. Visuospatial deficits in Parkinson's disease assessed by judgment of line orientation test: error analyses and practice effects. J Clin Exp Neuropsychol 2001; 23: 592–8.Google Scholar

Emre, M. Dementia associated with Parkinson's disease. Lancet Neurol 2003; 2: 229–37.Google Scholar

McPherson, S, Cummings, J. Neuropsychological aspects of Parkinson's disease and Parkinsonism. In Grant, I, Adams, KA, eds. Neuropsychological Assessment of Neuropsychiatric and Neuromedical Disorders. New York: Oxford University Press, 2009; 199–222.Google Scholar

Litvan, I, Mohr, E, Williams, J, Gomez, C, Chase, TN. Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease. J Neurol Neurosurg Psychiatry 1991; 54: 25–9.Google Scholar

Pillon, B, Dubois, B, Ploska, A, Agid, Y. Severity and specificity of cognitive impairment in Alzheimer's, Huntington's, and Parkinson's diseases and progressive supranuclear palsy. Neurology 1991; 41: 634–43.Google Scholar

Stern, Y, Marder, K, Tang, MX, Mayeux, R. Antecedent clinical features associated with dementia in Parkinson's disease. Neurology 1993; 43: 1690–2.Google Scholar

Ferreira, JJ, Katzenschlager, R, Bloem, BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol 2013; 20: 5–15.Google Scholar

Hanagasi, HA, Gurvit, H, Unsalan, P, et al. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov Disord 2011; 26: 1851–8.Google Scholar

Emre, M, Aarsland, D, Albanese, A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509–18.Google Scholar

Dubois, B, Tolosa, E, Katzenschlager, R, et al. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord 2012; 27: 1230–8.Google Scholar

Emre, M, Tsolaki, M, Bonuccelli, U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 969–77.Google Scholar

Aarsland, D Ballard, C, Walker, Z, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009; 8: 613–18.Google Scholar

Cerasa, A, Gioia, MC, Salsone, M, et al. Neurofunctional correlates of attention rehabilitation in Parkinson's disease: an explorative study. Neurol Sci 2014; 35: 1173–80.Google Scholar

Disbrow, EA, Russo, KA, Higginson, CI, et al. Efficacy of tailored computer-based neurorehabilitation for improvement of movement initiation in Parkinson's disease. Brain Res 2012; 1452: 151–64.Google Scholar

Mohlman, J, Chazin, D, Georgescu, B. Feasibility and acceptance of a nonpharmacological cognitive remediation intervention for patients with Parkinson disease. J Geriatr Psychiatry Neurol 2011; 24: 91–7.Google Scholar

Paris, AP, Saleta, HG, de la Cruz Crespo, Maraver M, et al. Blind randomized controlled study of the efficacy of cognitive training in Parkinson's disease. Mov Disord 2011; 26: 1251–8.Google Scholar

Sammer, G, Reuter, I, Hullmann, K, Kaps, M, Vaitl, D. Training of executive functions in Parkinson's disease. J Neurol Sci 2006; 248: 115–19.Google Scholar

Sinforiani, E, Banchieri, L, Zucchella, C, Pacchetti, C, Sandrini, G. Cognitive rehabilitation in Parkinson's disease. Arch Gerontol Geriatr Suppl 2004 (9): 387–91.Google Scholar

Reuter, I, Mehnert, S, Sammer, G, Oechsner, M, Engelhardt, M. Efficacy of a multimodal cognitive rehabilitation including psychomotor and endurance training in Parkinson's disease. J Aging Res 2012; 2012: 235765.Google Scholar

Naismith, SL, Mowszowski, L, Diamond, , K, Lewis, SJ. Improving memory in Parkinson's disease: a healthy brain ageing cognitive training program. Mov Disord 2013; 28: 1097–103.CrossRef Google Scholar PubMed

Nombela, C, Bustillo, PJ, Castell, PF, et al. Cognitive rehabilitation in Parkinson's disease: evidence from neuroimaging. Front Neurol 2011; 2: 82.Google Scholar

Pompeu, JE, Mendes, FA, Silva, KG, et al. Effect of Nintendo Wii-based motor and cognitive training on activities of daily living in patients with Parkinson's disease: a randomised clinical trial. Physiotherapy 2012; 98: 196–204.Google Scholar

Cruise, KE, Bucks, RS, Loftus, AM, et al. Exercise and Parkinson's: benefits for cognition and quality of life. Acta Neurol Scand 2011; 123: 13–19.Google Scholar

Nocera, JR, Amano, S, Vallabhajosula, S, Hass, CJ. Tai Chi exercise to improve non-motor symptoms of Parkinson's disease. J Yoga Phys Ther 2013; 3: 10.4172/2157-7595.1000137.Google Scholar

Ridgel, AL, Muller, MD, Kim, CH, Fickes, EJ, Mera, TO. Acute effects of passive leg cycling on upper extremity tremor and bradykinesia in Parkinson's disease. Phys Sportsmed 2011; 39: 83–93.Google Scholar

Tabak, R, Aquije, G, Fisher, BE. Aerobic exercise to improve executive function in Parkinson disease: a case series. J Neurol Phys Ther 2013; 37: 58–64.Google Scholar

Tanaka, K, Quadros, AC Jr, Santos, RF, Stella, F, Gobbi, LT, Gobbi, S. Benefits of physical exercise on executive functions in older people with Parkinson's disease. Brain Cogn 2009; 69: 435–41.Google Scholar

Boggio, PS, Fregni, F, Bermpohl, F, et al. Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson's disease and concurrent depression. Mov Disord 2005; 20: 1178–84.Google Scholar

Boggio, PS, Ferrucci, R, Rigonatti, SP, et al. Effects of transcranial direct current stimulation on working memory in patients with Parkinson's disease. J Neurol Sci 2006; 249: 31–8.CrossRef Google Scholar PubMed

Epstein, CM, Evatt, ML, Funk, A, et al. An open study of repetitive transcranial magnetic stimulation in treatment-resistant depression with Parkinson's disease. Clin Neurophysiol, 2007; 118: 2189–94.Google Scholar

Pal, E, Nagy, F, Aschermann, Z, Balazs, E, Kovacs, N. The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson's disease: a randomized, double-blind, placebo-controlled study. Mov Disord 2010; 25: 2311–17.Google Scholar

Sedlackova, S, Rektorova, I, Srovnalova, H, Rektor, I. Effect of high frequency repetitive transcranial magnetic stimulation on reaction time, clinical features and cognitive functions in patients with Parkinson's disease. J Neural Transm 2009; 116: 1093–101.Google Scholar

Srovnalova, H, Marecek, R, Rektorova, I. The role of the inferior frontal gyri in cognitive processing of patients with Parkinson's disease: a pilot rTMS study. Mov Disord 2011; 26: 1545–8.Google Scholar

Srovnalova, H, Marecek, R, Kubikova, R, Rektorova, I. The role of the right dorsolateral prefrontal cortex in the Tower of London task performance: repetitive transcranial magnetic stimulation study in patients with Parkinson's disease. Exp Brain Res 2012; 223: 251–7.Google Scholar

Furukawa, T, Izumi, S, Toyokura, M, Masakado, Y. Effects of low-frequency repetitive transcranial magnetic stimulation in Parkinson's disease. Tokai J Exp Clin Med 2009; 34: 63–71.Google Scholar

Fregni, F, Santos, CM, Myczkowski, ML, et al. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75: 1171–4.Google Scholar

Leroi, I, Brandt, J, Reich, SG, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004; 19: 1–8.Google Scholar

Ravina, B, Putt, M, Siderowf, A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005; 76: 934–9.Google Scholar

Trail, M, Protas, EJ, Lai, E (eds). Neurorehabilitation in Parkinson's disease: An Evidence-based Treatment Model. New Jersey: SLACK, Inc. 2008Google Scholar

Cicerone, KD, Dahlberg, C, Malec, JF, et al. Evidence-based cognitive rehabilitation: updated review of the literature from 1998 through 2002. Arch Phys Med Rehabil 2005; 86: 1681–92.Google Scholar

Loewenstein, DA, Acevedo, A, Czaja, SJ, Duara, R. Cognitive rehabilitation of mildly impaired Alzheimer disease patients on cholinesterase inhibitors. Am J Geriatr Psychiatry 2004; 12: 395–402.Google Scholar

Jean, L, Bergeron, ME, Thivierge, S, Simard, M. Cognitive intervention programs for individuals with mild cognitive impairment: systematic review of the literature. Am J Geriatr Psychiatry 2010; 18: 281–96.Google Scholar

Hindle, JV, Petrelli, A, Clare, L, Kalbe, E. Nonpharmacological enhancement of cognitive function in Parkinson's disease: a systematic review. Mov Disord 2013; 28: 1034–49.Google Scholar

Twamley, EW, Savla, GN, Zurhellen, CH, Heaton, RK, Jeste, DV. Development and pilot testing of a novel compensatory cognitive training intervention for people with psychosis. Am J Psychiatr Rehabil 2008; 11: 144–63.Google Scholar

Olazaran, J, Muniz, R, Reisberg, B, et al. Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease. Neurology 2004; 63: 2348–53.Google Scholar

Bronnick, K, Emre, M, Lane, R, Tekin, S, Aarsland, D. Profile of cognitive impairment in dementia associated with Parkinson's disease compared with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2007; 78: 1064–8.CrossRef Google Scholar PubMed

Achtman, RL, Green, CS, Bavelier, D. Video games as a tool to train visual skills. Restor Neurol Neurosci 2008; 26: 435–46.Google Scholar

Nasreddine, ZS, Phillips, NA, Bedirian, V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695–9.Google Scholar

Scatton, B, Javoy-Agid, F, Rouquier, L, Dubois, B, Agid, Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 1983; 275: 321–8.Google Scholar

Colcombe, SJ, Erickson, KI, Scalf, PE, et al. Aerobic exercise training increases brain volume in aging humans. J Gerontol A Biol Sci Med Sci 2006; 61: 1166–70.Google Scholar

Tanaka, H, Koenig, T, Pascual-Marqui, RD, et al. Event-related potential and EEG measures in Parkinson's disease without and with dementia. Dement Geriatr Cogn Disord 2000; 11: 39–45.Google Scholar

Barnikol, TT, Barnikol, UB, Kuhn, J, Lenartz, D, Tass, PA. Changes in apraxia after deep brain stimulation of the nucleus basalis meynert in a patient With Parkinson dementia syndrome. Mov Disord 2010; 25: 1519–20.Google Scholar

References

Jankovic, J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2007; 79: 368–76.Google Scholar

Lim, SY, Fox, SH, Lang, AE. Overview of the extranigral aspects of Parkinson disease. Arch Neurol 2009; 66: 167–72.Google Scholar

Barone, P, Antonini, A, Colosimo, C, et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009; 24: 1641–9.Google Scholar

Emre, M, Aarsland, D, Brown, R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22: 1689–707.Google Scholar

Aarsland, D, Bronnick, K, Williams-Gray, C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010; 75: 1062–9.Google Scholar

Litvan, I, Aarsland, D, Adler, CH, et al. MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord 2011; 26: 1814–24.Google Scholar

Watson, GS, Leverenz, JB. Profile of cognitive impairment in Parkinson's disease. Brain Pathol 2010; 20: 640–5.Google Scholar

Petersen, RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256: 183–194.Google Scholar

Aarsland, D, Brønnick, K, Larsen, JP, Tysnes, OB, Alves, G. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009; 72: 1121–6.Google Scholar

Litvan, I, Goldman, JG, Tröster, AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012; 27: 349–56.Google Scholar

Chou, KL, Amick, MM, Brandt, J, et al. A recommended scale for cognitive screening in clinical trials of Parkinson's disease. Mov Disord 2010; 25: 2501–7.Google Scholar

Dalrymple-Alford, JC, MacAskill, MR, Nakas, CT, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010; 75: 1717–25.Google Scholar

Emre, M, Aarsland, D, Albanese, A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509–18.Google Scholar

Klein, JC, Eggers, C, Kalbe, E, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010; 74: 885–92.Google Scholar

Rolinski, M, Fox, C, Maidment, I, McShane, R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev 2012; 3: CD006504.Google Scholar

Lipton, SA. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. J Alzheimers Dis 2004; 6 (Suppl.): S61–74.Google Scholar

Svenningsson, P, Westman, E, Ballard, C, Aarsland, D. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol 2012; 11: 697–707.Google Scholar

Marsh, L, Biglan, K, Gerstenhaber, M, Williams, JR. Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. Mov Disord 2009; 24: 277–82.Google Scholar

Weintraub, D, Mavandadi, S, Mamikonyan, E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 2010; 75: 448–55.Google Scholar

Parsons, TD, Rogers, SA, Braaten, AJ, Woods, SP, Tröster, AI. Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis. Lancet Neurol 2006; 5: 578–88.Google Scholar

Smeding, HM, Speelman, JD, Huizenga, HM, Schuurman, PR, Schmand, B. Predictors of cognitive and psychosocial outcome after STN-DBS in Parkinson's Disease. J Neurol Neurosurg Psychiatry 2011; 82: 754–60.Google Scholar

Buschert, V, Bokde, AL, Hampel, H. Cognitive intervention in Alzheimer disease. Nat Rev Neurol 2010; 6: 508–17.Google Scholar

Hindle, JV, Petrelli, A, Clare, L, Kalbe, E. Nonpharmacological enhancement of cognitive function in Parkinson's disease: a systematic review. Mov Disord 2013; 28: 1034–49.Google Scholar

References

Weintraub, D, Burn, D. Parkinson's disease: the quintessential neuropsychiatric disorder. Mov Disord 2011; 26: 1022–31.Google Scholar

Muller, B, Assus, J, Herlofson, K, Larsen, JP, Tysnes, OB. Importance of motor vs non-motor symptoms for health-related quality of life in early Parkinson's disease. Park Rel Disord 2013; 19: 1027–32.Google Scholar

Rana, AQ, Athar, A, Owlia, A, et al. Impact of ethnicity on non-motor symptoms of Parkinson's disease. J Park Dis 2012; 2: 281–5.Google Scholar

Aarsland, D, Larsen, JP, Tanberg, E, Laake, K. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Ger Soc 2000; 48: 938–42.Google Scholar

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, Text Revision. Washington, DC: American Psychiatric Association Press, 1994.Google Scholar

Leentjens, AF, Dujardin, K, Marsh, L, et al. Anxiety and motor fluctuations in Parkinson's disease: a cross sectional observational study. Park Rel Disord 2012; 18: 1084–8.Google Scholar

Poletti, M, Bonuccelli, U. Personality traits in patients with Parkinson's disease: assessment and clinical implications. J Neurol 2012; 259: 1029–38.Google Scholar

Noyce, AJ, Bestwick, JP, Silveira-Moriyama, L, et al. Meta-analysis of early non-motor symptoms and risk factors for Parkinson's disease. Ann Neurol 2012; 72: 893–901.Google Scholar

Schifitto, G, Friedman, JH, Oakes, D, et al. Fatigue in levodopa-naive subjects with Parkinson's disease. Neurology 2008; 71: 481–5.Google Scholar

Jeliffe, SE. The parkinsonian body posture: some considerations on unconscious hostility. Psychoanal Rev 1940; 27: 467–79.Google Scholar

Sands, I. The type of personality susceptible to Parkinson's disease. J Mt Sinai Hosp 1942; 9: 792–4.Google Scholar

Poewe, W, Karamat, E, Kemmler, GW, Gerstenbrand, F. The premorbid personality of patients with Parkinson's disease: a comparative study with healthy controls and patients with essential tremor. Adv Neurol 1990; 53: 339–42.Google Scholar

Glosser, G, Clark, C, Freundlich, B, et al. A controlled investigation of current and premorbid personality: characteristics of Parkinson's disease patients. Mov Disord 1995; 19: 201–6.Google Scholar

Hubble, JP, Venkatesh, R, Hassanein, RE, Gray, C, Koller, WC. Personality and depression in Parkinson's disease. J Ner Ment Dis 1993; 181: 657–62.Google Scholar

Bower, JH, Grossardt, BR, Maraganore, DM, et al. Anxious personality predicts an increased risk of Parkinson's disease. Mov Disord 2010; 25: 2105–13.Google Scholar

Arabia, G, Grossardt, BR, Colligan, RC, et al. Novelty seeking and introversion do not predict the long-term risk of Parkinson disease. Neurology 2010; 75: 349–57.Google Scholar

Vieregge, P, Hagenah, J, Heberlein, I, Klein, C, Ludin, HP. Parkinson's disease in twins: a follow up study. Neurology 1999; 53: 566–72.Google Scholar

Starkstein, SE. Apathy in Parkinson's disease: diagnostic and etiological dilemmas. Mov Disord 2012; 27: 174–8.Google Scholar

Chase, TN Apathy in neuropsychiatric diseases: diagnosis, pathophysiology and treatment. Neurotox Res 2011; 19: 266–78.Google Scholar

Robert, P, Onyike, CU, Leentjens, AF, et al. Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders. Eur Psychiatry 2009; 24: 98–104.Google Scholar

Marin, RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 1991; 3: 243–54.Google Scholar

Drijgers, RL, Dujardin, K, Reijnders, JS, Defebvre, L, Leentjens, AF. Validation of diagnostic criteria for apathy in Parkinson's disease. Parkinson Rel Disord 2010; 16: 656–60.Google Scholar

Leentjens, AF, Dujardin, K, Marsh, L, et al. Anxiety rating scales in Parkinson's disease: critique and recomendations. Mov Disord 2008; 23: 2105–25.Google Scholar

Kirsch-Darrow, L, Fernandez, HF, et al. Dissociating apathy and depression in Parkinson disease. Neurology 2006; 67: 33–8.Google Scholar

Starkstein, S, Merello, M, Jorge, R, et al. The syndromal validity and nosological position of apathy in Parkinson's disease. Mov Disord 2009; 15: 1211–16.Google Scholar

Dujardin, K, Sockeel, P, Devos, D, et al. Characteristics of apathy in Parkinson's disease. Mov Disord 2007; 22: 778–84.Google Scholar

Pedersen, KF, Larsen, JP, Alves, G, Aarsland, D. Prevalence and clinical correlates of apathy in Parkinson's disease: a community-based study. Park Rel Disord 2009; 15: 295–9.Google Scholar

Starkstein, S, Leentjens, AF. The nosological position of apathy in clinical practice. J Neurol Neurosurg Psychiatry 2008; 79: 1088–92.Google Scholar

Nirenberg, MJ. Dopamine agonist withdrawal syndrome: implications for patient care. Drugs Aging 2013; 30: 587–92.Google Scholar

Leentjens, AF, Dujardin, K, Marsh, L, et al. Anxiety rating scales in Parkinson's disease: a validation study of the Hamilton anxiety rating scale, the Beck anxiety inventory and the Hospital anxiety and depression rating scale. Mov Disord 2011; 26: 407–15.Google Scholar

Dissanayaka, NAD, Selbach, A, Matheson, S, et al. Anxiety disorders in Parkinson's disease: prevalence and risk factors. Mov Disord 2010; 25: 838–45.Google Scholar

Shulman, LM, Taback, RL, Rabinstein, AA, Weiner, WJ. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Park Rel Disord 2002; 8: 193–7.Google Scholar

Liu, AA, Boxham, CE, Klufas, MA, et al. Clinical predictors of frequent patient telephone calls in Parkinson's disease. Park Rel Disord 2011; 17: 95–9.Google Scholar

American Psychiatric Association. Diagnostic and Statistical Manual V. Washington, DC: American Psychiatric Press, 2013.Google Scholar

Walsh, K, Bennet, G. Parkinson's disease and anxiety. Postgrad Med 2001; 7: 89–93.Google Scholar

Ponton, GM, Williams, JR, Anderson, DE, et al. Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease. Mov Disord 2009; 24: 1333–8.Google Scholar

Fleminger, S. Left sided Parkinson's disease is associated with greater anxiety and depression. Psychol Med 1991; 21: 629–38.Google Scholar

Leentjens, AF, Dujardin, K, Marsh, L, et al. Anxiety and motor fluctuations in Parkinson's disease: a cross sectional observational study. Park Rel Disord 2012; 18: 1084–8.Google Scholar

Dotchin, CL, Jusabani, A, Walker, RW. Non-motor symptoms in a prevalent population with Parkinson's disease in Tanzania. Park Rel Disord 2009; 15: 457–60.Google Scholar

Friedman, JH. Parkinson's disease psychosis: Update. Behav Neurol 2013; 27: 469–77.Google Scholar

Zhu, K, van Hilten, JJ, Putter, H, Marinus, J. Risk factors for hallucinations in Parkinson's disease: results from a large prospective cohort study. Mov Disord 2013; 28: 755–62.Google Scholar

Ravina, B, Marder, K, Fernandez, HH, et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord 2007; 22: 1061–8.Google Scholar

Chou, KL, Messing, S, Oakes, D, et al. Drug-induced psychosis in Parkinson's disease: phenomenology and correlations among psychiatric rating scales. Clin Neuropharm 2005; 28: 215–9.Google Scholar

Yoritaka, A, Shimo, Y, Takanashi, M, et al. Motor and non-motor symptoms of 1453 patients with Parkinson's disease: Prevalence and risks. Park Rel Disord 2013; 19: 725–31.Google Scholar

Seppi, K, Weintraub, D, Coelho, M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011; (Suppl. 3): S42–80.Google Scholar

Friedman, JH. Pimavanserin in Parkinson's disease psychosis. Expert Opin Pharmacother 2013; 14: 1969–75.Google Scholar

Chen, JJ, Marsh, L. Depression in Parkinson's disease: identification and management. Pharmacotherapy 2013; 33: 972–83.Google Scholar

Rocha, FL, Murad, MGR, Stumpf, BP, Hara, C, Fuzikawa, C. Antidepressants for depression in Parkinson's disease: systematic review and meta-analysis. J Psychopharmacol 2013; 27: 417–23.Google Scholar

Reijnders, JS, Ehrt, U, Weber, WE, Aarsland, D, Leentjens, AF. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008; 23: 183–9.Google Scholar

Hughes, TA, Ross, HF, Mindham, RH, Spokes, EG. Mortality in Parkinson's disease and its association with dementia and depression. Acta Neurol Scand 2004; 110: 118–23.Google Scholar

Ravina, B, Camicioli, R, Como, PG, et al. The impact of depressive symptoms in early Parkinson disease. Neurology 2007; 69: 342–7.Google Scholar

Schrag, A, Hovris, A, Morley, D, Quinn, N, Jahanshahi, M. Caregiver burden in Parkinson's disease is closely associated with psychiatric symptoms, falls and disability. Park Rel Dsord 2005; 12: 35–41.Google Scholar

Global Parkinson's Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord 2002; 17: 60–7.Google Scholar

Ravina, B, Elm, J, Camicioli, R, et al. The course of depressive symptoms in early Parkinson's disease. Mov Disord 2009; 24: 1306–11.Google Scholar

Weintraub, D, Morales, KH, Moberg, PJ, et al. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord 2005; 20: 1161–9.Google Scholar

Richard, IH, McDermott, MP, Kurlan, R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012; 78: 1229–36.Google Scholar

Barone, P, Poewe, W, Albrecht, S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomized double blind placebo controlled trial. Lancet Neurol 2010; 9: 573–80.Google Scholar

Moellentine, C, Rummans, T, Ahlskog, JE, et al. Effectiveness of ECT in patients with parkinsonism. J Neuropsychiatr Clin Neurosci 1998; 10: 187–93.Google Scholar

Yang, S, Sajatovic, M, Walter, BL. Psychosocial interventions for depression and anxiety in Parkinson's disease. J Geratr Psychiatr Neurol 2012; 25: 113–21.Google Scholar

Friedman, JH, Abrantes, A, Sweet, LH. Fatigue in Parkinson's disease. Exp Opin Pharmacother 2011; 12: 1999–2007.Google Scholar

Lou, JS, Kearns, G, Benice, T, et al. Levodopa improves physical fatigue in Parinson's disease: a double-blind placebo-controlled study. Mov Disord 2003; 18: 1108–14.Google Scholar

Brown, RG, Dittner, A, Findley, L, Wessely, SC. The Parkinson fatigue scale. Parkinson Rel Disord 2005; 11: 49–55.Google Scholar

Krupp, LB, LaRocca, NG, Muir-Nash, J, Steinberg, AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121–3.Google Scholar

Valko, PO, Waldvogel, D, Weller, M, et al. Fatigue and excessive daytime sleepiness in idiopathic Parkinson's disease differently correlate with motor symptoms, depression and dopaminergic treatment. Eur J Neurol 2010; 17: 1428–36.Google Scholar

Alves, G, Wentzel-Larsen, T, Larsen, JP. Is fatigue an independent and persistent symptom in patients with Parkinson's disease? Neurol 2004; 63: 1908–11.Google Scholar

Friedman, JH, Brown, RG, Comella, C, et al. Fatigue in Parkinson's disease: a review. Mov Disord 2007; 22: 297–308.Google Scholar

Friedman, J, Friedman, H. Fatigue in Parkinson's disease. Neurol 1993; 43: 2016–8.Google Scholar

Van Hilten, JJ, Weggeman, M, van der Velde, EA, et al. Sleep, excessive daytime sleepiness and fatigue in Parkinson's disease. J Neural Transm Park Dis Dement Secct 1993; 5: 235–44.Google Scholar

Karlsen, K, Larsen, JP, Tandberg, E, Jørgensen, K. Fatigue in patients with Parkinson's disease. Mov Disord 1999; 14: 237–41.Google Scholar

Saez-Francas, N, Hernandez-Vera, J, Corominos Roso, M, Alegre Martín, J, Casas Brugué, M. The association of apathy with central fatigue in patients with Parkinson's disease. Behav Neurosci 2013; 127: 237–44.Google Scholar

Garber, CE, Friedman, JH. Effects of fatigue on physical activity and function in patients with Parkinson's disease. Neurology 2003; 60: 1119–24.Google Scholar

Pavese, N, Metta, V, Bose, SK, Chaudhuri, KR, Brooks, DJ. Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. Brain 2010; 133: 3434–43.Google Scholar

Mendonca, DA, Menezes, K, Jog, MS. Methylphenidate improve fatigue scores in Parkinson's disease: a randomized controlled trial. Mov Disord 2007; 22: 2070–6.Google Scholar

References

Tang, J, Strafella, AP. The frontostriatal circuitry and behavioral complications in PD. Parkinsonism Relat Disord 2012; 18 (Suppl. 1): S104–6.Google Scholar

Aarons, S, Peisah, C, Wijeratne, C. Neuropsychiatric effects of Parkinson's disease treatment. Australas J Ageing 2012; 31: 198–202.Google Scholar

Huot, P, Fox, SH. The serotonergic system in motor and non-motor manifestations of Parkinson's disease. Exp Brain Res 2013; 230: 463–76.Google Scholar

Rabinak, CA, Nirenberg, MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010; 67: 58–63.Google Scholar

Connolly, BS, Fox, SH. Drug treatments for the neuropsychiatric complications of Parkinson's disease. Expert Rev Neurother 2012; 12: 1439–49.Google Scholar

Friedman, JH. Parkinson disease psychosis: update. Behav Neurol 2013; 27: 469–77.Google Scholar

Ravina, B, Marder, K, Fernandez, HH, et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord 2007; Jun 15; 22: 1061–8.Google Scholar

Mack, J, Rabins, P, Anderson, K, et al. Prevalence of psychotic symptoms in a community-based Parkinson disease sample. Am J Geriatr Psychiatry 2012; 20: 123–32.Google Scholar

Goldman, JG. New thoughts on thought disorders in Parkinson's disease: review of current research strategies and challenges. Parkinsons Dis 2011; 2011: 675630.Google Scholar

Emre, M, Aarsland, D, Albanese, A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509–18.Google Scholar

Meltzer, HY, Massey, BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 2011; 11: 59–67.Google Scholar

Ballanger, B, Strafella, AP, van Eimeren, T, et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 2010; 67: 416–21.Google Scholar

Hindle, JV. The practical management of cognitive impairment and psychosis in the older Parkinson's disease patient. J Neural Transm 2013; 120: 649–53.Google Scholar

Weintraub, D, Chen, P, Ignacio, RV, Mamikonyan, E, Kales, HC. Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Arch Neurol 2011; 68: 899–904.Google Scholar

Cummings, J, Isaacson, S, Mills, R, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 2014; 383: 533–40.Google Scholar

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, Text Revision. Washington, DC: American Psychiatric Association Press, 1994.Google Scholar

Evans, AH, Strafella, AP, Weintraub, D, Stacy, M. Impulsive and compulsive behaviors in Parkinson's disease. Mov Disord 2009; 24: 1561–70.Google Scholar

Maier, F, Merkl, J, Ellereit, AL, et al. Hypomania and mania related to dopamine replacement therapy in Parkinson's disease. Parkinsonism Relat Disord 2014; 20: 421–7.Google Scholar

Voon, V, Fox, SH. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 2007; 64: 1089–96.Google Scholar

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edn. Washington, DC: American Psychiatric Publishing, 2013.Google Scholar

Evans, AH, Katzenschlager, R, Paviour, D, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004; 19: 397–405.Google Scholar

Okai, D, Samuel, M, Askey-Jones, S, David, AS, Brown, RG. Impulse control disorders and dopamine dysregulation in Parkinson's disease: a broader conceptual framework. Eur J Neurol 2011; 18: 1379–83.Google Scholar

Driver-Dunckley, E, Samanta, J, Stacy, M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 2003; 61: 422–3.Google Scholar

Weintraub, D, Koester, J, Potenza, MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010; 67: 589–95.Google Scholar

Garcia-Ruiz, PJ, Martinez Castrillo, JC, Alonso-Canovas, A, et al. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry 2014; 85: 840–4.Google Scholar

Gerlach, M, Double, K, Arzberger, T, et al. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm 2003; 110: 1119–27.Google Scholar

Yin, HH, Knowlton, BJ. The role of the basal ganglia in habit formation. Nat Rev Neurosci 2006; 7: 464–76.Google Scholar

Rao, H, Mamikonyan, E, Detre, JA, et al. Decreased ventral striatal activity with impulse control disorders in Parkinson's disease. Mov Disord 2010; 25: 1660–9.Google Scholar

Voon, V, Rizos, A, Chakravartty, R, et al. Impulse control disorders in Parkinson's disease: decreased striatal dopamine transporter levels. J Neurol Neurosurg Psychiatry 2014; 85: 148–52.Google Scholar

Weintraub, D, Mamikonyan, E, Papay, K, et al. Questionnaire for impulsive-compulsive disorders in Parkinson's disease – rating scale. Mov Disord 2012; 27: 242–7.Google Scholar

Sohtaoğlu, M, Demiray, DY, Kenangil, G, Ozekmekçi, S, Erginöz, E. Long term follow-up of Parkinson's disease patients with impulse control disorders. Parkinsonism Relat Disord 2010; 16: 334–7.Google Scholar

Catalán, MJ, de Pablo-Fernández, E, Villanueva, C, et al. Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson's disease. Mov Disord 2013; 28: 2007–10.Google Scholar

Katzenschlager, R. Dopamine dysregulation syndrome in Parkinson's disease. J Neurol Sci 2011; 310: 271–5.Google Scholar

Kringelbach, ML, Berridge, KC. Towards a functional neuroanatomy of pleasure and happiness. Trends Cogn Sci. 2009; 13: 479–87.Google Scholar

Giovannoni, G, O'sullivan, JD, Turner, K, Manson, AJ, Lees, AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000; 68: 423–8.Google Scholar

Cilia, R, Siri, C, Canesi, M, et al. Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome. J Neurol Neurosurg Psychiatry 2014; 85: 311–8.Google Scholar

Evans, AH, Pavese, N, Lawrence, AD, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006; 59: 852–8.Google Scholar

Linazasoro, G. Dopamine dysregulation syndrome and levodopa-induced dyskinesias in Parkinson disease: common consequences of anomalous forms of neural plasticity. Clin Neuropharmacol 2009; 32: 22–7.Google Scholar

Okun, MS, Weintraub, D. Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa? Mov Disord 2013; 28: 1915–9.Google Scholar

Pondal, M, Marras, C, Miyasaki, J, et al. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry 2013; 84: 130–5.Google Scholar

Limotai, N, Oyama, G, Go, C, et al. Addiction-like manifestations and Parkinson's disease: a large single center 9-year experience. Int J Neurosci 2012; 122: 145–53.Google Scholar

Thobois, S, Ardouin, C, Lhommée, E, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010; 133: 1111–27.Google Scholar

Nirenberg, MJ. Dopamine agonist withdrawal syndrome: implications for patient care. Drugs Aging 2013; 30: 587–92.Google Scholar

Cunnington, AL, White, L, Hood, K. Identification of possible risk factors for the development of dopamine agonist withdrawal syndrome in Parkinson's disease. Parkinsonism Relat Disord 2012; 18: 1051–2.Google Scholar

Bronstein, JM, Tagliati, M, Alterman, RL, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol 2011; 68: 165.Google Scholar

Voon, V, Kubu, C, Krack, P, Houeto, JL, Tröster, AI. Deep brain stimulation: neuropsychological and neuropsychiatric issues. Mov Disord 2006; 21 (Suppl. 14): S305–27.Google Scholar

Greenberg, BD, Gabriels, LA, Malone, DA Jr, et al. Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience. Mol Psychiatry. 2010; 15: 64–79.Google Scholar

Temel, Y, Kessels, A, Tan, S, et al. Behavioural changes after bilateral subthalamic stimulation in advanced Parkinson disease: a systematic review. Parkinsonism Relat Disord 2006; 12: 265–72.Google Scholar

Funkiewiez, A, Ardouin, C, Krack, P, et al. Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease. Mov Disord 2003; 18: 524–30.Google Scholar

Follett, KA, Weaver, FM, Stern, M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med 2010; 362: 2077–91.Google Scholar

Witt, K, Daniels, C, Volkmann, J. Factors associated with neuropsychiatric side effects after STN-DBS in Parkinson's disease. Parkinsonism Relat Disord 2012; 18(Suppl. 1): S168–70.Google Scholar

Temel, Y. Limbic effects of high-frequency stimulation of the subthalamic nucleus. Vitam Horm 2010; 82: 47–63.Google Scholar

Okun, MS, Fernandez, HH, Wu, SS, et al. Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Ann Neurol 2009; 65: 586–95.Google Scholar

Odekerken, VJ, van Laar, T, Staal, MJ, et al. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial. Lancet Neurol 2013; 12: 37–44.Google Scholar

Klaming, L, Haselager, P. Did my brain implant make me do it? Questions raised by DBS regarding psychological continuity, responsibility for action and mental competence. Neuroethics 2013; 6: 527–39.Google Scholar

Rodriguez, RL, Fernandez, HH, Haq, I, Okun, MS. Pearls in patient selection for deep brain stimulation. Neurologist. 2007; 13: 253–60.Google Scholar

Broen, M, Duits, A, Visser-Vandewalle, V, Temel, Y, Winogrodzka, A. Impulse control and related disorders in Parkinson's disease patients treated with bilateral subthalamic nucleus stimulation: a review. Parkinsonism Relat Disord 2011; 17: 413–7.Google Scholar

Kirsch-Darrow, L, Zahodne, LB, Marsiske, M, et al. The trajectory of apathy after deep brain stimulation: from pre-surgery to 6 months post-surgery in Parkinson's disease. Parkinsonism Relat Disord 2011; 17: 182–8.Google Scholar

Campbell, MC, Black, KJ, Weaver, PM, et al. Mood response to deep brain stimulation of the subthalamic nucleus in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2012; 24: 28–36.Google Scholar

Voon, V, Krack, P, Lang, AE, et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain 2008; 131: 2720–8.Google Scholar

Weintraub, D, Duda, JE, Carlson, K, et al. Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson's disease: results from a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2013; 84: 1113–18.Google Scholar

Struhal, W, Guger, M, Hödl, S, et al. Attempted suicide under high dose dopaminergic therapy including apomorphine. Wien Klin Wochenschr 2012; 124: 461–3.Google Scholar

Pandya, M, Machado, A, Malone, D. Depression in humans: the ventral capsule/ventral striatum. In: Denys, D, Feenstra, E, Schuurman, R, eds. Deep Brain Stimulation: A New Frontier in Psychiatry; 2012; 95–102.Google Scholar

Saleh, C. How to treat DBS-induced mania? J Neurol Sci 2011; 301: 116.Google Scholar

Moum, SJ, Price, CC, Limotai, N, et al. Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. PLoS One 2012; 7: e29768.Google Scholar

Eusebio, A, Witjas, T, Cohen, J, et al. Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease. J Neurol Neurosurg Psychiatry 2013; 84: 868–74.Google Scholar

Shotbolt, P, Moriarty, J, Costello, A, et al. Relationships between deep brain stimulation and impulse control disorders in Parkinson's disease, with a literature review. Parkinsonism Relat Disord 2012; 18: 10–16.Google Scholar

References

Dickson, DW, Fujishiro, H, Orr, C, et al. Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat Disord 2009; 15 (Suppl. 3): S1–5.Google Scholar

Iranzo, A. Parkinson disease and sleep: sleep–wake changes in the premotor stage of Parkinson disease; impaired olfaction and other prodromal features. Curr Neurol Neurosci Rep 2013; 13: 373.Google Scholar

Tolosa, E, Gaig, C, Santamaria, J, Compta, Y. Diagnosis and the premotor phase of Parkinson disease. Neurology 2009; 72 (Suppl.): S12–20.Google Scholar

Boeve, BF. Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. Lancet Neurol 2013; 12: 469–82.Google Scholar

Louter, M, Aarden, WC, Lion, J, Bloem, BR, Overeem, S. Recognition and diagnosis of sleep disorders in Parkinson's disease. J Neurol 2012; 259: 2031–40.Google Scholar

Lees, AJ, Blackburn, NA, Campbell, VL. The nighttime problems of Parkinson's disease. Clin Neuropharmacol 1988; 11: 512–9.Google Scholar

Zoccolella, S, Savarese, M, Lamberti, P, et al. Sleep disorders and the natural history of Parkinson's disease: the contribution of epidemiological studies. Sleep Med Rev 2011; 15: 41–50.Google Scholar

Comella, CL. Sleep disorders in Parkinson's disease: an overview. Mov Disord 2007; 22 (Suppl. 17): S367–73.Google Scholar

Chaudhuri, KR, Logishetty, K. Dopamine receptor agonists and sleep disturbances in Parkinson's disease. Parkinsonism Relat Disord 2009; 15 (Suppl. 4): S101–4.Google Scholar

Oerlemans, WG, de Weerd, AW. The prevalence of sleep disorders in patients with Parkinson's disease. A self-reported, community-based survey. Sleep Med 2002; 3: 147–9.Google Scholar

Videnovic, A, Golombek, D. Circadian and sleep disorders in Parkinson's disease. Exp Neurol 2013; 243: 45–56.Google Scholar

Iranzo, A. Sleep–wake changes in the premotor stage of Parkinson disease. J Neurol Sci 2011; 310: 283–5.Google Scholar

Menza, M, Dobkin, RD, Marin, H, Bienfait, K. Sleep disturbances in Parkinson's disease. Mov Disord 2010; 25 (Suppl. 1): S117–22.Google Scholar

Schenck, CH, Bundlie, SR, Ettinger, MG, Mahowald, MW. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep 1986; 9: 293–308.Google Scholar

Comella, CL, Nardine, TM, Diederich, NJ, Stebbins, GT. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease. Neurology 1998; 51: 526–9.Google Scholar

Montplaisir, J, Gagnon, JF, Fantini, ML, et al. Polysomnographic diagnosis of idiopathic REM sleep behavior disorder. Mov Disord 2010; 25: 2044–51.Google Scholar

Nielsen, T, Svob, C, Kuiken, D. Dream-enacting behaviors in a normal population. Sleep 2009; 32: 1629–36.Google Scholar

Gagnon, JF, Bedard, MA, Fantini, ML, et al. REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology 2002; 59: 585–9.Google Scholar

Iranzo, A, Molinuevo, JL, Santamaria, J, et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 2006; 5: 572–7.Google Scholar

Iranzo, A, Valldeoriola, F, Lomena, F, et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 2011; 10: 797–805.Google Scholar

Stockner, H, Iranzo, A, Seppi, K, et al. Midbrain hyperechogenicity in idiopathic REM sleep behavior disorder. Mov Disord 2009; 24: 1906–9.Google Scholar

McCarter, SJ, Boswell, CL, St Louis, EK, et al. Treatment outcomes in REM sleep behavior disorder. Sleep Med 2013; 14: 237–42.Google Scholar

Allen, RP, Picchietti, D, Hening, WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4: 101–19.Google Scholar

Garcia-Borreguero, D, Egatz, R, Winkelmann, J, Berger, K. Epidemiology of restless legs syndrome: the current status. Sleep Med Rev 2006; 10: 153–67.Google Scholar

Lugaresi, E, Coccagna, G, Gambi, D, Berti, CG, Poppi, M. Symonds’ nocturnal myoclonus. Electroencephalogr Clin Neurophysiol 1967; 23: 289.Google Scholar

PoeweW, Högl B. Akathisia, , restless legs and periodic limb movements in sleep in Parkinson's disease. Neurology 2004; 63 (Suppl. 3): S12–16.Google Scholar

Baumann, CR, Marti, I, Bassetti, CL. Restless legs symptoms without periodic limb movements in sleep and without response to dopaminergic agents: a restless legs-like syndrome? Eur J Neurol 2007; 14: 1369–72.Google Scholar

Chotinaiwattarakul, W, Dayalu, P, Chervin, RD, Albin, RL. Risk of sleep-disordered breathing in Parkinson's disease. Sleep Breath 2011; 15: 471–8.Google Scholar

Arnulf, I, Konofal, E, Merino-Andreu, M, et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology 2002; 58: 1019–24.Google Scholar

Cochen de Cock, V, Abouda, M, Leu, S, et al. Is obstructive sleep apnea a problem in Parkinson's disease? Sleep Med 2010; 11: 247–52.Google Scholar

Trotti, LM, Bliwise, DL. No increased risk of obstructive sleep apnea in Parkinson's disease. Mov Disord 2010; 25: 2246–9.Google Scholar

Tandberg, E, Larsen, JP, Karlsen, K. Excessive daytime sleepiness and sleep benefit in Parkinson's disease: a community-based study. Mov Disord 1999; 14: 922–7.Google Scholar

Tan, EK, Lum, SY, Fook-Chong, SM, et al. Evaluation of somnolence in Parkinson's disease: comparison with age- and sex-matched controls. Neurology 2002; 58: 465–8.Google Scholar

Razmy, A, Lang, AE, Shapiro, CM. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol 2004; 61: 97–102.Google Scholar

Ondo, WG, Dat, VK, Khan, H, et al. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology 2001; 57: 1392–6.Google Scholar

Frucht, S, Rogers, JD, Greene, PE, Gordon, MF, Fahn, S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999; 52: 1908–10.Google Scholar

Paus, S, Brecht, HM, Koster, J, et al. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 2003; 18: 659–67.Google Scholar

Chaudhuri, KR. The dopaminergic basis of sleep dysfunction and non motor symptoms of Parkinson's disease: evidence from functional imaging. Exp Neurol 2009; 216: 247–8.Google Scholar

Monti, JM, Jantos, H. The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking. Prog Brain Res 2008; 172: 625–46.Google Scholar

Grinberg, LT, Rueb, U, Alho, AT, Heinsen, H. Brainstem pathology and non-motor symptoms in PD. J Neurol Sci 2010; 289: 81–8.Google Scholar

Monti, JM, Monti, D. The involvement of dopamine in the modulation of sleep and waking. Sleep Med Rev 2007; 11: 113–33.Google Scholar

Garcia-Lorenzo, D, Longo-Dos, SC, Ewenczyk, C, et al. The coeruleus/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson's disease. Brain 2013; 136): 2120–9.Google Scholar

Lu, J, Jhou, TC, Saper, CB. Identification of wake-active dopaminergic neurons in the ventral periaqueductal gray matter. J Neurosci 2006; 26: 193–202.Google Scholar

Suzuki, K, Miyamoto, M, Miyamoto, T, Iwanami, M, Hirata, K. Sleep disturbances associated with Parkinson's disease. Parkinsons Dis 2011; 2011: 219056.Google Scholar

Happe, S, Baier, PC, Helmschmied, K, et al. Association of daytime sleepiness with nigrostriatal dopaminergic degeneration in early Parkinson's disease. J Neurol 2007; 254: 1037–43.Google Scholar

Iranzo, A, Lomena, F, Stockner, H, et al. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]. Lancet Neurol 2010; 9: 1070–7.Google Scholar

Witkovsky, P. Dopamine and retinal function. Doc Ophthalmol 2004; 108: 17–40.Google Scholar

Boeve, BF, Silber, MH, Saper, CB, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 2007; 130: 2770–88.Google Scholar

Scherfler, C, Frauscher, B, Schocke, M, et al. White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: a diffusion-tensor imaging and voxel-based morphometry study. Ann Neurol 2011; 69: 400–7.Google Scholar

Diederich, NJ, McIntyre, DJ. Sleep disorders in Parkinson's disease: many causes, few therapeutic options. J Neurol Sci 2012; 314: 12–9.Google Scholar

Chaudhuri, KR, Prieto-Jurcynska, C, Naidu, Y, et al. The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord 2010; 25: 704–9.Google Scholar

Högl, B, Arnulf, I, Comella, C, et al. Scales to assess sleep impairment in Parkinson's disease: critique and recommendations. Mov Disord 2010; 25: 2704–16.Google Scholar

Zesiewicz, TA, Sullivan, KL, Arnulf, I, et al. Practice parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 2010; 74: 924–31.Google Scholar

Chaudhuri, KR, Schapira, AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8: 464–74.Google Scholar

Leeman, AL, O’Neill, CJ, Nicholson, PW, et al. Parkinson's disease in the elderly: response to and optimal spacing of night time dosing with levodopa. Br J Clin Pharmacol 1987; 24: 637–43.Google Scholar

Stocchi, F, Barbato, L, Nordera, G, Berardelli, A, Ruggieri, S. Sleep disorders in Parkinson's disease. J Neurol 1998; 245 (Suppl. 1): S15–18.Google Scholar

Comella, CL, Morrissey, M, Janko, K. Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy. Neurology 2005; 64: 1450–1.Google Scholar

Reuter, I, Ellis, CM, Ray, CK. Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurol Scand 1999; 100: 163–7.Google Scholar

Poewe, WH, Rascol, O, Quinn, N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007; 6: 513–20.Google Scholar

Pahwa, R, Stacy, MA, Factor, SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007; 68: 1108–15.Google Scholar

Romigi, A, Stanzione, P, Marciani, MG, et al. Effect of cabergoline added to levodopa treatment on sleep–wake cycle in idiopathic Parkinson's disease: an open label 24-hour polysomnographic study. J Neural Transm 2006; 113: 1909–13.Google Scholar

Högl, B, Rothdach, A, Wetter, TC, Trenkwalder, C. The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease. Neuropsychopharmacology 2003; 28: 1866–70.Google Scholar

Trenkwalder, C, Kies, B, Rudzinska, M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011; 26: 90–9.Google Scholar

Takanashi, M, Shimo, Y, Hatano, T, Oyama, G, Hattori, N. Efficacy and safety of a once-daily extended-release formulation of pramipexole switched from an immediate-release formulation in patients with advanced Parkinson's disease: results from an open-label study. Drug Res (Stuttg) 2013; 63: 639–43.Google Scholar

Dowling, GA, Mastick, J, Colling, E, et al. Melatonin for sleep disturbances in Parkinson's disease. Sleep Med 2005; 6: 459–66.Google Scholar

Medeiros, CA, Carvalhedo de Bruin, PF, Lopes, LA, et al. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study. J Neurol 2007; 254: 459–64.Google Scholar

Abe, K, Hikita, T, Sakoda, S. [A hypnotic drug for sleep disturbances in patients with Parkinson's disease]. No To Shinkei 2005; 57: 301–5 (in Japanese).Google Scholar

Juri, C, Chana, P, Tapia, J, Kunstmann, C, Parrao, T. Quetiapine for insomnia in Parkinson disease: results from an open-label trial. Clin Neuropharmacol 2005; 28: 185–7.Google Scholar

Linazasoro, G, Marti Masso, JF, Suarez, JA. Nocturnal akathisia in Parkinson's disease: treatment with clozapine. Mov Disord 1993; 8: 171–4.Google Scholar

Dresler, M, Spoormaker, VI, Beitinger, P, et al. Neuroscience-driven discovery and development of sleep therapeutics. Pharmacol Ther 2013; 141: 300–4.Google Scholar

Rios, RS, Creti, L, Fichten, C, et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease – a randomized study. Parkinsonism Relat Disord 2013; 19: 670–5.Google Scholar

Morgenthaler, T, Kramer, M, Alessi, C, et al. Practice parameters for the psychological and behavioral treatment of insomnia: an update. An American Academy of Sleep Medicine Report. Sleep 2006; 29: 1415–19.Google Scholar

Iranzo, A, Santamaria, J, Rye, DB, et al. Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD. Neurology 2005; 65: 247–52.Google Scholar

Olson, EJ, Boeve, BF, Silber, MH. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain 2000; 123: 331–9.Google Scholar

Schmidt, MH, Koshal, VB, Schmidt, HS. Use of pramipexole in REM sleep behavior disorder: results from a case series. Sleep Med 2006; 7: 418–23.Google Scholar

Kumru, H, Iranzo, A, Carrasco, E, et al. Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson disease. Sleep 2008; 31: 1418–21.Google Scholar

Antonini, A, Tesei, S, Zecchinelli, A, et al. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life. Mov Disord 2006; 21: 1119–22.Google Scholar

Kunz, D, Mahlberg, R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res 2010; 19: 591–6.Google Scholar

Kotagal, V, Albin, RL, Muller, ML, et al. Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. Ann Neurol 2012; 71: 560–8.Google Scholar

Nomura, T, Kawase, S, Watanabe, Y, Nakashima, K. Use of ramelteon for the treatment of secondary REM sleep behavior disorder. Intern Med 2013; 52: 2123–6.Google Scholar

Trotti, LM, Bliwise, DL. Treatment of the sleep disorders associated with Parkinson's disease. Neurotherapeutics 2013; 11: 68–77.Google Scholar

Howell, MJ, Arneson, PA, Schenck, CH. A novel therapy for REM sleep behavior disorder (RBD). J Clin Sleep Med 2011; 7: 639–644A.Google Scholar

Bruin, VM, Bittencourt, LR, Tufik, S. Sleep–wake disturbances in Parkinson's disease: current evidence regarding diagnostic and therapeutic decisions. Eur Neurol 2012; 67: 257–67.Google Scholar

Giles, TL, Lasserson, TJ, Smith, BH, et al. Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 2006; CD001106.Google Scholar

Högl, B, Saletu, M, Brandauer, E, et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 2002; 25: 905–9.Google Scholar

Adler, CH, Caviness, JN, Hentz, JG, Lind, M, Tiede, J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord 2003; 18: 287–93.Google Scholar

Ondo, WG, Fayle, R, Atassi, F, Jankovic, J. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry 2005; 76: 1636–9.Google Scholar

Devos, D, Krystkowiak, P, Clement, F, et al. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 2007; 78: 470–5.Google Scholar

Postuma, RB, Lang, AE, Munhoz, RP, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology 2012; 79: 651–8.Google Scholar

O'suilleabhain, PE, Dewey, RB Jr. Contributions of dopaminergic drugs and disease severity to daytime sleepiness in Parkinson disease. Arch Neurol 2002; 59: 986–9.Google Scholar

Breen, DP, Williams-Gray, CH, Mason, SL, Foltynie, T, Barker, RA. Excessive daytime sleepiness and its risk factors in incident Parkinson's disease. J Neurol Neurosurg Psychiatry 2013; 84: 233–4.Google Scholar

Fasano, A, Daniele, A, Albanese, A. Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation. Lancet Neurol 2012; 11: 429–42.Google Scholar

Monaca, C, Ozsancak, C, Jacquesson, JM, et al. Effects of bilateral subthalamic stimulation on sleep in Parkinson's disease. J Neurol 2004; 251: 214–8.Google Scholar

Iranzo, A, Valldeoriola, F, Santamaria, J, Tolosa, E, Rumia, J. Sleep symptoms and polysomnographic architecture in advanced Parkinson's disease after chronic bilateral subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002; 72: 661–4.Google Scholar

Arnulf, I, Bejjani, BP, Garma, L, et al. Improvement of sleep architecture in PD with subthalamic nucleus stimulation. Neurology 2000; 55: 1732–4.Google Scholar

Hjort, N, Ostergaard, K, Dupont, E. Improvement of sleep quality in patients with advanced Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus. Mov Disord 2004; 19: 196–9.Google Scholar

Lyons, KE, Pahwa, R. Effects of bilateral subthalamic nucleus stimulation on sleep, daytime sleepiness, and early morning dystonia in patients with Parkinson disease. J Neurosurg 2006; 104: 502–5.Google Scholar

Chahine, LM, Ahmed, A, Sun, Z. Effects of STN DBS for Parkinson's disease on restless legs syndrome and other sleep-related measures. Parkinsonism Relat Disord 2011; 17: 208–11.Google Scholar

Driver-Dunckley, E, Evidente, VG, Adler, CH, et al. Restless legs syndrome in Parkinson's disease patients may improve with subthalamic stimulation. Mov Disord 2006; 21: 1287–9.Google Scholar

Kedia, S, Moro, E, Tagliati, M, Lang, AE, Kumar, R. Emergence of restless legs syndrome during subthalamic stimulation for Parkinson disease. Neurology 2004; 63: 2410–12.Google Scholar

References

Parkinson, J. An Essay on the Shaking Palsy. London: Whittingham and Rowland. 1817.Google Scholar

Charcot, J. Lectures on Diseases of the Nervous System. London: The New Sydenham Society. 1877.Google Scholar

Gowers, W. A Manual of Disease of the Nervous System. Philadelphia: Blakiston. 1888.Google Scholar

Beiske, AG, Loge, JH, Rønningen, A, Svensson, E. Pain in Parkinson's disease: prevalence and characteristics. Pain 2009; 141: 173–7.Google Scholar

Perez-Lloret, S, Rey, MV, Dellapina, E, et al. Emerging analgesic drugs for Parkinson's disease. Expert Opin Emerg Drugs 2012; 17: 157–71.Google Scholar

Lee, MA, Walker, RW, Hildreth, TJ, Prentice, WM. A survey of pain in idiopathic Parkinson's disease. J Pain Symptom Manage 2006; 32: 462–9.Google Scholar

Defazio, G, Berardelli, A, Fabbrini, G, et al. Pain as a nonmotor symptom of Parkinson disease: evidence from a case–control study. Arch Neurol 2008; 65: 1191–4.Google Scholar

O'sullivan, SS, Williams, DR, Gallagher, DA, et al. Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study. Mov Disord 2008; 23: 101–6.Google Scholar

Burkey, AR, Carstens, E, Jasmin, L. Dopamine reuptake inhibition in the rostral agranular insular cortex produces antinociception. J Neurosci 1999; 19: 4169–79.Google Scholar

Barnes, CD, Fung, SJ, Adams, WL. Inhibitory effects of substantia nigra on impulse transmission from nociceptors. Pain 1979; 6: 207–15.Google Scholar

Chudler, EH, Dong, WK. The role of the basal ganglia in nociception and pain. Pain 1995; 60: 3–38.Google Scholar

Honey, CR, Stoessl, AJ, Tsui, JK, Schulzer, M, Calne, DB. Unilateral pallidotomy for reduction of parkinsonian pain. J Neurosurg 1999; 91: 198–201.Google Scholar

Loher, TJ, Burgunder, JM, Weber, S, Sommerhalder, R, Krauss, JK. Effect of chronic pallidal deep brain stimulation on off period dystonia and sensory symptoms in advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 2002; 73: 395–9.Google Scholar

Fil, A, Cano-de-la-Cuerda, R, Muñoz-Hellín, E, et al. Pain in Parkinson disease: a review of the literature. Parkinsonism Relat Disord 2013; 19: 285–94; discussion 285.Google Scholar

Willis, WD, Westlund, KN. Neuroanatomy of the pain system and of the pathways that modulate pain. J Clin Neurophysiol 1997; 14: 2–31.Google Scholar

Braak, H, Del Tredici, K, Rüb, U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197–211.Google Scholar

Scherder, E, Wolters, E, Polman, C, Sergeant, J, Swaab, D. Pain in Parkinson's disease and multiple sclerosis: its relation to the medial and lateral pain systems. Neurosci Biobehav Rev 2005; 29: 1047–56.Google Scholar

Nolano, M, Provitera, V, Estraneo, A, et al. Sensory deficit in Parkinson's disease: evidence of a cutaneous denervation. Brain 2008; 131: 1903–11.Google Scholar

Braak, H, Sastre, M, Bohl, E JR, de Vos, RAI, Del Tredici, K. Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol 2007; 113: 421–9.Google Scholar

Barone, P. Neurotransmission in Parkinson's disease: beyond dopamine. Eur J Neurol 2010; 17: 364–76.Google Scholar

Millan, MJ. The induction of pain: an integrative review. Prog Neurobiol 1999; 57: 1–164.Google Scholar

Juri, C, Rodriguez-Oroz, M, Obeso, JA. The pathophysiological basis of sensory disturbances in Parkinson's disease. J Neurolog Sci 2010; 289: 60–5.Google Scholar

Wood, PB. Role of central dopamine in pain and analgesia. Expert Rev Neurother 2008; 8: 781–97.Google Scholar

Brefel-Courbon, C, Payoux, P, Thalamas, C, et al. Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord 2005; 20: 1557–63.Google Scholar

Djaldetti, R, Shifrin, A, Rogowski, Z, et al. Quantitative measurement of pain sensation in patients with Parkinson disease. Neurology 2004; 62: 2171–5.Google Scholar

Dellapina, E, Gerdelat-Mas, A, Ory-Magne, F, et al. Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord 2011; 26: 153–7.Google Scholar

Goetz, CG, Tanner, CM, Levy, M, Wilson, RS, Garron, DC. Pain in Parkinson's disease. Mov Disord 1986; 1: 45–9.Google Scholar

Nègre-Pagès, L, Regragui, W, Bouhassira, D, Grandjean, H, Rascol, O. Chronic pain in Parkinson's disease: the cross-sectional French DoPaMiP survey. Mov Disord 2008; 23: 1361–9.Google Scholar

Tinazzi, M, Del Vesco, C, Fincati, E, et al. Pain and motor complications in Parkinson's disease. J Neurol Neurosurg Psychiatry 2006; 77: 822–5.Google Scholar

Rollman, GB, Lautenbacher, S. Sex differences in musculoskeletal pain. Clin J Pain 2001; 17: 20–4.Google Scholar

Scott, B, Borgman, A, Engler, H, Johnels, B, Aquilonius, SM. Gender differences in Parkinson's disease symptom profile. Acta Neurol Scand 2000; 102: 37–43.Google Scholar

Hanagasi, HA, Akat, S, Gurvit, H, Yazici, J, Emre, M. Pain is common in Parkinson's disease. Clin Neurol Neurosurg 2011; 113: 11–13.Google Scholar

Ehrt, U, Larsen, JP, Aarsland, D. Pain and its relationship to depression in Parkinson disease. Am J Geriatr Psychiatry 2009; 17: 269–75.Google Scholar

Goetz, CG, Wilson, RS, Tanner, CM, Garron, DC. Relationships among pain, depression, and sleep alterations in Parkinson's disease. Adv Neurol 1987; 45: 345–7.Google Scholar

Snider, SR, Fahn, S, Isgreen, WP, Cote, LJ. Primary sensory symptoms in parkinsonism. Neurology 1976; 26: 423–9.Google Scholar

Ford, B. Pain in Parkinson's disease. Mov Disord 2010; 25( Suppl. 1): S98–103.Google Scholar

Del Sorbo, F, Albanese, A. Clinical management of pain and fatigue in Parkinson's disease. Parkinsonism Relat Disord 2012; 18 (Suppl. 1): S233–6.Google Scholar

Bissonnette, B. Pseudorheumatoid deformity of the feet associated with parkinsonism. J Rheumatol 1986; 13: 825–6.Google Scholar

Santos-García, D, Abella-Corral, J, Aneiros-Díaz, Á, et al. [Pain in Parkinson's disease: prevalence, characteristics, associated factors, and relation with other non motor symptoms, quality of life, autonomy, and caregiver burden]. Rev Neurol 2011; 52: 385–93 (in Spanish).Google Scholar

Duvoisin, RC, Marsden, CD. Note on the scoliosis of Parkinsonism. J Neurol Neurosurg Psychiatry 1975; 38: 787–93.Google Scholar

Broetz, D, Eichner, M, Gasser, T, Weller, M, Steinbach, JP. Radicular and nonradicular back pain in Parkinson's disease: a controlled study. Mov Disord 2007; 22: 853–6.Google Scholar

Schnitzer, TJ. Update on guidelines for the treatment of chronic musculoskeletal pain. Clin Rheumatol 2006; 25 (Suppl. 1): S22–9.Google Scholar

Tolosa, E, Compta, Y. Dystonia in Parkinson's disease. J Neurol 2006; 253 (Suppl. VII): 7–13.Google Scholar

Kidron, D, Melamed, . Forms of dystonia in patients with Parkinson's disease. Neurology 1987; 37: 1009–11.Google Scholar

Sophie, M, Ford, B. Management of pain in Parkinson's disease. CNS Drugs 2012; 26: 937–48.Google Scholar

Karlsborg, M, Korbo, L, Regeur, L, Glad, A. Duodopa pump treatment in patients with advanced Parkinson's disease. Dan Med Bull 2010; 57: A4155.Google Scholar

Lees, AJ. Dopamine agonists in Parkinson's disease: a look at apomorphine. Fundam Clin Pharmacol 1993; 7: 121–8.Google Scholar

Sanford, M, Scott, LJ. Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease. CNS Drugs 2011; 25: 699–719.Google Scholar

Stocchi, F, Ruggieri, S, Antonini, A, et al. Subcutaneous lisuride infusion in Parkinson's disease: clinical results using different modes of administration. J Neural Transm Suppl 1988; 27: 27–33.Google Scholar

Cordivari, C, Misra, VP, Catania, S, Lees, AJ. Treatment of dystonic clenched fist with botulinum toxin. Mov Disord 2001; 16: 907–13.Google Scholar

Pacchetti, C, Albani, G, Martignoni, E, et al. “Off” painful dystonia in Parkinson's disease treated with botulinum toxin. Mov Disord 1995; 10: 333–6.Google Scholar

Kim, HJ, Jeon, BS, Paek, SH. Effect of deep brain stimulation on pain in Parkinson disease. J Neurolog Sci 2011; 310: 251–5.Google Scholar

Oshima, H, Katayama, Y, Morishita, T, et al. Subthalamic nucleus stimulation for attenuation of pain related to Parkinson disease. J Neurosurg 2012; 116: 99–106.Google Scholar

Witjas, T, Kaphan, E, Régis, J, et al. Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson's disease. Mov Disord 2007; 22: 1729–34.Google Scholar

Thomas, A, Iacono, D, Luciano, AL, et al. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75: 141–3.Google Scholar

Metman, LV, Del Dotto, P, LePoole, K, et al. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999; 56: 1383–6.Google Scholar

Durif, F. Foot dystonia treatment by botulinum toxin injections in Parkinson disease: efficiency of injections made in extrinsic muscle (flexor digitorum longus muscle) compared to intrinsic muscle (flexor digitorum brevis or quadratus plantae muscles) (RBHP 2008). ClinicalTrials.gov, 2009; NCT00909883. Available from: http://clinicaltrials.gov/ct2/show/NCT00909883?term=botulinum+pain+parkinson's&rank=1.Google Scholar

Yucel, A, Yilmaz, O, Babaoglu, S, Acar, M, Degirmenci, B. Sonographic findings of the median nerve and prevalence of carpal tunnel syndrome in patients with Parkinson's disease. Eur J Radiol 2008; 67: 546–50.Google Scholar

Preston, DN, Grimes, JD. Radial compression neuropathy in advanced Parkinson's disease. Arch Neurol 1985; 42: 695–6.Google Scholar

Kurlan, R, Baker, P, Miller, C, Shoulson, I. Severe compression neuropathy following sudden onset of parkinsonian immobility. Arch Neurol 1985; 42: 720.Google Scholar

Wasner, G, Deuschl, G. Pains in Parkinson disease – many syndromes under one umbrella. Nature reviews. Neurology 2012; 8: 284–94.Google Scholar

Shulman, LM, Minagar, A, Sharma, K, Weiner, WJ. Amantadine-induced peripheral neuropathy. Neurology 1999; 53: 1862–5.Google Scholar

Rajabally, YA, Martey, J. Neuropathy in Parkinson disease: prevalence and determinants. Neurology 2011; 77: 1947–50.Google Scholar

Toth, C, Breithaupt, K, Ge, S, et al. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol 2010; 68: 28–36.Google Scholar

Comella, CL, Goetz, CG. Akathisia in Parkinson's disease. Mov Disord 1994; 9: 545–9.Google Scholar

Krishnan, PR, Bhatia, M, Behari, M. Restless legs syndrome in Parkinson's disease: a case-controlled study. Mov Disord 2003; 18: 181–5.Google Scholar

Ondo, WG, Vuong, KD, Jankovic, J. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol 2002; 59: 421–4.Google Scholar

Ford, B, Louis, ED, Greene, P, Fahn, S. Oral and genital pain syndromes in Parkinson's disease. Mov Disord 1996; 11: 421–6.Google Scholar

Schestatsky, P, Kumru, H, Valls-Solé, J, et al. Neurophysiologic study of central pain in patients with Parkinson disease. Neurology 2007; 69: 2162–9.Google Scholar

Gierthmühlen, J, Arning, P, Binder, A, et al. Influence of deep brain stimulation and levodopa on sensory signs in Parkinson's disease. Mov Disord 2010; 25: 1195–202.Google Scholar

Allain, H, Schuck, S, Mauduit, N. Depression in Parkinson's disease. BMJ 2000; 320: 1287–8.Google Scholar

Djaldetti, R, Yust-Katz, S, Kolianov, V, Melamed, E, Dabby, R. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin Neuropharmacol 30: 201–5.Google Scholar

Goodwin, VA, Richards, SH, Taylor, RS, Taylor, AH, Campbell, JL. The effectiveness of exercise interventions for people with Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2008; 23: 631–40.Google Scholar

Reuter, I, Mehnert, S, Leone, P, et al. Effects of a flexibility and relaxation programme, walking, and nordic walking on Parkinson's disease. J Aging Res 2011; 2011: 232473.Google Scholar

Ferry, P, Johnson, M, Wallis, P. Use of complementary therapies and non-prescribed medication in patients with Parkinson's disease. Postgrad Med J 2002; 78: 612–4.Google Scholar

Kim, SR, Lee, TY, Kim, MS, Lee, MC, Chung, SJ. Use of complementary and alternative medicine by Korean patients with Parkinson's disease. Clin Neurol Neurosurg 2009; 111: 156–60.Google Scholar

Cristian, A, Katz, M, Cutrone, E, Walker, RH. Evaluation of acupuncture in the treatment of Parkinson's disease: a double-blind pilot study. Mov Disord 2005; 20: 1185–8.Google Scholar

Shulman, LM, Wen, X, Weiner, WJ, et al. Acupuncture therapy for the symptoms of Parkinson's disease. Mov Disord 2002; 17: 799–802.Google Scholar

Kim, HJ, Paek, SH, Kim, JY, et al. Chronic subthalamic deep brain stimulation improves pain in Parkinson disease. J Neurol 2008; 255: 1889–94.Google Scholar

Lomarev, MP, Kanchana, S, Bara-Jimenez, W, et al. Placebo-controlled study of rTMS for the treatment of Parkinson's disease. Mov Disord 2006; 21: 325–31.Google Scholar

Kodama, M, Kasahara, T, Hyodo, M, et al. Effect of low-frequency repetitive transcranial magnetic stimulation combined with physical therapy on L-dopa-induced painful off-period dystonia in Parkinson's disease. Am J Phys Med Rehabil 2011; 90: 150–5.Google Scholar

Bestmann, S, Baudewig, J, Siebner, HR, Rothwell, JC, Frahm, J. Functional MRI of the immediate impact of transcranial magnetic stimulation on cortical and subcortical motor circuits. Eur J Neurosci 2004; 19: 1950–62.Google Scholar

Maarrawi, J, Peyron, R, Mertens, P, et al. Motor cortex stimulation for pain control induces changes in the endogenous opioid system. Neurology 2007; 69: 827–34.Google Scholar

Gabis, L, Shklar, B, Baruch, YK, et al. Pain reduction using transcranial electrostimulation: a double blind “active placebo” controlled trial. J Rehabil Med 2009; 41: 256–61.Google Scholar

Rintala, DH, Tan, G, Willson, P, Bryant, MS, Lai, ECH. Feasibility of using cranial electrotherapy stimulation for pain in persons with Parkinson's disease. Parkinsons Dis 2010; 2010: 569154.Google Scholar

Jankovic, J, Leder, S, Warner, D, Schwartz, K. Cervical dystonia: clinical findings and associated movement disorders. Neurology 1991; 41: 1088–91.Google Scholar

Morren, JA, Lugo, R, Gálvez-jiménez, N. EMG findings in Parkinson's disease patients with peripheral nerve injuries. In: The Movement Disorder Society's 15th International Congress of Parkinson's Disease and Movement Disorders, Toronto, Abstact 809, 2011.Google Scholar

Toth, C, Brown, MS, Furtado, S, Suchowersky, O, Zochodne, D. Neuropathy as a potential complication of levodopa use in Parkinson's disease. Mov Disord 2008; 23: 1850–9.Google Scholar

Müller, T, van Laar, T, Cornblath, DR, et al. Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery. Parkinsonism Relat Disord 2013; 19: 501–7; discussion 501.Google Scholar

Urban, PP, Wellach, I, Faiss, S, et al. Subacute axonal neuropathy in Parkinson's disease with cobalamin and vitamin B6 deficiency under duodopa therapy. Mov Disord 2010; 25: 1748–52.Google Scholar

Manca, D, Cossu, G, Murgia, D, et al. Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy. Mov Disord 2009; 24: 2293–4.Google Scholar

Antonini, A, Isaias, IU, Canesi, M, et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007; 22: 1145–9.Google Scholar

Klostermann, F, Jugel, C, Müller, T, Marzinzik, F. Malnutritional neuropathy under intestinal levodopa infusion. J Neural Transm 2012; 119: 369–72.Google Scholar

Meppelink, AM, Nyman, R, van Laar, T, et al. Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease. Mov Disord 2011; 26: 331–4.Google Scholar

van Hilten, JJ, Weggeman, M, van der Velde, EA, et al. Sleep, excessive daytime sleepiness and fatigue in Parkinson's disease. J Neural Transm 1993; 5: 235–44.Google Scholar

Quittenbaum, BH, Grahn, B. Quality of life and pain in Parkinson's disease: a controlled cross-sectional study. Parkinsonism Relat Disord 2004; 10: 129–36.Google Scholar

Caap-Ahlgren, M, Dehlin, O. Insomnia and depressive symptoms in patients with Parkinson's disease. Relationship to health-related quality of life. An interview study of patients living at home. Arch Gerontol Geriatr 2001; 32: 23–33.Google Scholar

Politis, M, Wu, K, Molloy, S, et al. Parkinson's disease symptoms: the patient's perspective. Mov Disord 2010; 25: 1646–51.Google Scholar

Book contents

Section II - Management of Nonmotor Symptoms of Parkinson's Disease

Access options

References

References

References

References

References

References

References

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive